In our previous paper, long-term oral administration of pemafibrate improved blood glucose levels, modulated cellular metabolism, upregulated PPARα target genes in the liver (not in the retina), and increased serum levels of FGF21, to protect against diabetes-induced retinal dysfunction (amplitudes in oscillatory potentials) in mice [175]. Here, PPARA is linked to diabetes mellitus.